Price increases for functional polymers for pharmaceutical applications
The company’s priority is to enhance the quality and availability of supply and services. In this context significant investments were made to improve reliability, and to satisfy more stringent regulatory requirements. Additionally, increased wages and raw material costs are already above pre 2009 levels.
These investments will further improve the company’s infrastructure, strengthen business continuity and create competitive advantages for its pharmaceutical customers.
Other news from the department price development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.